“Pediococcus acidilactici PA53 emerges as a safe and effective intervention for enhancing digestive function and modulating inflammatory pathways in older adults,” wrote scientists from Henan University of Technology and the First Affiliated Hospital of Zhengzhou University. PA53Explore related questionsPediococcus acidilactici PA53 is a strain developed, manufactured, and commercially supplied by China’s Wecare Probiotics. The participants were randomly assigned to receive either placebo or Pediococcus acidilactici PA53 at a daily dose of 30 billion colony forming units (CFUs) for eight weeks. “PA53 supplementation illustrated beneficial effects on fecal microbiota and well-being in elderly individuals, suggesting its potential as a probiotic intervention,” wrote the researchers. “Pediococcus acidilactici PA53 Improves Emotional Well-Being and Gut Health While Modulating Microbiota Composition in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial”.